(NEW YORK) – XYZ Corporation Announces Positive Topline Results from Phase III Study of Drug A in Leukemia Patients

XYZ Corporation announced positive topline results today from a pivotal study of Drug A in the treatment of nearly 1,000 newly diagnosed patients with acute myeloid leukemia (AML). The study met its primary endpoints of improved overall response rate and duration of response in patients receiving Drug A compared with those receiving standard of care. A complete data set from the trial will be presented at the 2011 American Society of Hematology Annual Meeting in December.

In this randomized, Phase III trial, 987 patients with newly diagnosed AML were randomized to receive either Drug A or the current standard therapy (Drug F/Drug G combination). The trial's objective was to determine if Drug A improved overall survival and duration of response compared with the standard arm. In an independent review of the data, Drug A achieved an overall response rate of 89 percent and a median duration of response of 12.3 months in patients who had not received prior treatment. Drug A was well-tolerated, and no significant differences in the side effects between the two arms were observed.

“We are extremely excited about these positive results and the promise that Drug A holds for improving the lives of patients diagnosed with AML,” said Robert Brady, chief executive officer of XYZ Corporation. “We look forward to presenting all the details of this study at the 53rd Annual Meeting of the American Society of Hematology meeting in San Diego.”

AML, a cancer of the bone marrow characterized by rapid growth of abnormal white blood cells, can progress quickly if not treated. It is one of the more common forms of leukemia in adults and occurs more often in people over the age of 65.

[Insert boilerplate about XYZ Corporation]